BAM
NMTC icon

Belpointe Asset Management’s NeuroOne Medical Technologies NMTC Stock Holding History

Belpointe Asset Management’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.2K Buy
+12,500
New +$60K ﹤0.01% 1054
2023
Q1 		– Sell
-114
Closed -$818 – 3811
2022
Q4 		$818 Buy
+114
New +$1.02K ﹤0.01% 3474

Other funds holding NMTC

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Belpointe Asset Management's NMTC Position: Q1 2026 in Review

Belpointe Asset Management opened a new position in NeuroOne Medical Technologies (NMTC) in Q1 2026: 12,500 shares worth $58.2K. The stake represents ﹤0.01% of the portfolio and ranks #1054 among its holdings. This is a return to the name: Belpointe Asset Management previously reported a position in NMTC as recently as Q4 2022.

Belpointe Asset Management first reported a position in NMTC in Q4 2022 and has held it in 2 quarters since. 32 funds tracked by Wall St. Rank hold NMTC as of Q1 2026.

  • Belpointe Asset Management held 12,500 shares of NeuroOne Medical Technologies worth $58.2K as of Q1 2026.
  • NeuroOne Medical Technologies was a new Belpointe Asset Management position in Q1 2026.
  • NeuroOne Medical Technologies made up ﹤0.01% of Belpointe Asset Management's portfolio in Q1 2026, its #1054 holding.
  • Belpointe Asset Management first reported a position in NeuroOne Medical Technologies in Q4 2022 and has held it in 2 quarters since.
  • 32 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q1 2026.

Based on Belpointe Asset Management's 13F filing for Q1 2026, filed 28 Apr 2026.